Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
J Pathol. 2011 Jan;223(2):274-82. doi: 10.1002/path.2807. Epub 2010 Nov 16.
In contrast to classifications for the majority of solid tumours, non-Hodgkin's lymphomas have been defined on the basis of their genetic alterations for many years, providing a biologically highly relevant classification. However, for aggressive B cell lymphomas, which unfortunately is the most prevalent group of lymphomas in adults, the stratification is less optimal. Gene expression profiling, analyses of chromosomal alterations and functional assays have been instrumental in dissecting these tumours to support the distinction of essentially different diseases, such as diffuse large B cell lymphoma and Burkitt's lymphoma, and now start to identify the dominant driving oncogenetic pathways that may serve as rational therapeutic targets in this essentially heterogeneous group. In this review, the molecular background and the consequences of the molecular alterations in the context of the consequences for treatment in aggressive B cell lymphoma are discussed.
与大多数实体瘤的分类不同，非霍奇金淋巴瘤多年来一直基于其遗传改变来定义，提供了具有高度生物学相关性的分类。然而，对于侵袭性 B 细胞淋巴瘤，不幸的是，它是成人中最常见的淋巴瘤类型，其分层效果并不理想。基因表达谱分析、染色体改变分析和功能测定在剖析这些肿瘤方面发挥了重要作用，支持区分本质上不同的疾病，如弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤，并开始确定主导性的致癌基因途径，这些途径可能成为这个本质上异质性群体的合理治疗靶点。在这篇综述中，讨论了侵袭性 B 细胞淋巴瘤中分子改变的分子背景及其对治疗结果的影响。
